The Biological Computing Co.
Category: AI Infrastructure
A biotechnology and AI infrastructure company developing 'Bionodes'—computational platforms that utilize living, lab-grown neurons to execute AI models with extreme energy efficiency. The Biological Computing Co. was founded in 2022. The company is led by Alexander Ksendzovsky. Based in San Francisco, USA. Team size: 10-50. Total funding raised: $25.0M. Latest round: Seed. Key investors include ["Primary Venture Partners","Builders VC","E1 Ventures","Tusk Ventures","Refactor Capital"].
- Founded
- 2022
- Headquarters
- San Francisco, USA
- Team size
- 10-50
- Total funding
- $25.0M
Value proposition
Provides a radical alternative to silicon-based hardware by leveraging the natural efficiency of biological neural networks, aiming to reduce the massive energy consumption and heat production of traditional AI data centers.
Products and solutions
["Bionode Platform (Biological processing units)","Biological Adapters (Interface technology for digital-to-biological signal conversion)","TBC Computing Cloud (Proposed access layer for biological computation)","Proprietary Bio-AI Integration Software"]
Unique value
Unlike neuromorphic silicon chips that mimic brain structure, TBC uses actual living biological neurons grown in vitro to perform real-time computational tasks and pattern recognition.
Target customer
AI researchers, high-performance computing (HPC) centers, enterprise AI developers, and organizations focused on sustainable/green AI infrastructure.
Industries served
["Artificial Intelligence Infrastructure","Biotechnology","Cloud Computing","Sustainability & Green Tech"]
Technology advantage
Biological neurons are orders of magnitude more energy-efficient than silicon transistors; TBC’s advantage lies in its 'Biological Adapter' technology which allows standard AI foundation models to communicate with living tissue.
How they differentiate
TBC differentiates through its 'Biological Adapter' technology, which allows standard digital foundation models to interface directly with living neurons. Unlike competitors focusing on reinforcement learning or biological sensing, TBC targets high-performance AI inference with extreme energy efficiency.
Main competitors
["Cortical Labs","FinalSpark","Koniku"]
Key partnerships
["NVIDIA Inception Program","University of Maryland School of Medicine (Clinical/Research affiliation)","Primary Venture Partners (Lead Investor)","Builders VC","E1 Ventures"]
Notable customers
["University of Maryland School of Medicine (Research Partner)"]
Major milestones
["Raised $25M Seed round led by Primary Venture Partners in Feb 2026","Accepted into the NVIDIA Inception program for AI startups","Developed proprietary 'Bionode' architecture for biological AI computation","CEO Alexander Ksendzovsky received the Lucien Rubenstein Award"]
Growth metrics
Early-stage R&D; currently scaling 'Bionode' capacity and biological-digital throughput; member of NVIDIA Inception program.
Market positioning
Deep-tech AI infrastructure pioneer and 'Wetware-as-a-Service' challenger.
Geographic focus
North America (HQ in San Francisco) with global reach via proposed cloud-based biological computing access.
Patents and IP
Proprietary IP surrounding the 'Bionode' architecture and biological-digital interface adapters (specific patent numbers not publicly disclosed).
About Alexander Ksendzovsky
Alexander Ksendzovsky is a neurosurgeon-scientist and entrepreneur. He is an Associate Professor of Neurosurgery and Director of Epilepsy Surgery at the University of Maryland School of Medicine. He holds an MD from Chicago Medical School and a PhD in Neuroscience from the University of Virginia, followed by a fellowship at Yale School of Medicine. He previously co-founded NeuroRPM, a digital health company utilizing AI for Parkinson's monitoring.
Official website: https://www.tbc.co/